Layne Hilton, an attorney in Meyer Wilson’s Mass Torts practice, has been appointed to serve on the Plaintiffs’ Steering Committee for the In re Valsartan, Losartan and Irbesartan Products Liability Litigation by the Hon. Robert Kugler of the District of New Jersey. In addition to generally serving on the Discovery, Law and Briefing, and Third-Party Payor committees, Layne was also appointed to serve as the co-chair of the Class Action committee. Since the beginning of the litigation, Layne has been integrally involved in many aspects of the case, including conducting 30(b)(6) depositions of company witnesses, conducting briefing related to Rule 12(b)(6) and Rule 23 Class Certification, working with experts on developing reports, and arguing discovery issues before the Court.
The litigation relates to certain batches of generic Valsartan, Losartan and Irbesartan which became contaminated with N-nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) but were nevertheless sold to US consumers for years. NDMA and NDEA are highly potent carcinogenic compounds and have been identified as “cohorts of concern” by world regulatory agencies due to their propensity for causing genetic mutations. N-Nitroso compounds such as NDMA or NDEA serve no legitimate function aside from being used by researchers to induce cancer in laboratory animals. As detailed in the master complaint, the Plaintiffs allege that this years-long contamination was a result of systemic and pervasive quality assurance failings occurring at manufacturing facilities in China and India operated by Zhejiang Huahai Pharmaceuticals, Mylan Pharmaceuticals, Teva Pharmaceuticals, Torrent Pharmaceuticals, Aurobindo Pharmaceuticals, and Hetero Labs Limited. In 2018, upon discovering that these companies had been manufacturing and selling generic products containing a carcinogen for years, the FDA initiated an unprecedented recall for all unexpired batches of these products. Due to the observed and documented grossly non-compliant quality assurance practices, the FDA also placed many of these companies facilities on import alert, preventing the products manufactured from these facilities from even crossing the border into the United States.
The Plaintiffs in the litigation seek recovery for either 1) the economic loss claims for the cost of the drug; 2) the cost of medical monitoring because of taking the drugs, or 3) for personal injuries suffered by those who developed certain cancers because of their ingestion of these defectively manufactured products.
If you would like to speak to someone about a potential claim related to your purchase and/or consumption of these products, please contact Meyer Wilson at 866-827-6537